Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

681
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
681
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.2K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.2K
Development of Immunocompetence01:22

Development of Immunocompetence

467
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
467

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Metabolic Risk in Childhood Brain Cancer Survivors with Childhood-Onset Growth Hormone Deficiency.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same author

Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study.

EClinicalMedicine·2026
Same author

Plasticity under pressure: biology and detection of lineage switch in acute leukemia.

Leukemia·2026
Same author

Aging restricts maturation of CXCL13<sup>+</sup> T follicular helper cells in human immunity.

Cell reports·2026
Same author

Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort study.

The Lancet. Child & adolescent health·2026
Same author

CellFuse Enables Multimodal Integration of Single-Cell and Spatial Proteomics Data for Systems-Level Analysis in Cancer.

Cancer research·2026

Related Experiment Video

Updated: Sep 23, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.4K

Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again.

Adrienne H Long1, Daniel A Morgenstern2, Amaury Leruste3

  • 1Division of Hematology, Oncology, and Stem Cell Transplant, Department of Pediatrics, Stanford University, Stanford, CA.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 17, 2022
PubMed
Summary

Immune checkpoint inhibitors (ICIs) show limited success in most pediatric cancers due to low immunogenicity. However, specific subsets, like hypermutated or SMARCB1-deficient tumors, demonstrate promising responses to ICIs, warranting further investigation.

More Related Videos

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.5K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Related Experiment Videos

Last Updated: Sep 23, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.4K
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.5K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Area of Science:

  • Pediatric Oncology
  • Immunotherapy
  • Cancer Biology

Background:

  • Immune checkpoint inhibitors (ICIs) augment anti-tumor T-cell responses.
  • ICIs are effective in adult cancers but show limited efficacy in unselected pediatric cancers.
  • Pediatric cancers generally have lower immunogenicity and fewer neoantigens compared to adult cancers.

Purpose of the Study:

  • To review the evolving role of ICIs in pediatric cancer treatment.
  • To identify pediatric cancer subsets that may benefit from ICI therapy.
  • To understand the biological basis for differential responses to ICIs in childhood cancers.

Main Methods:

  • Review of existing clinical trial data for ICIs in pediatric cancers.
  • Analysis of immunogenicity and neoantigen load in pediatric versus adult tumors.
  • Examination of preliminary data for specific pediatric cancer subsets showing response to ICIs.

Main Results:

  • Single-agent ICIs have shown infrequent responses in most pediatric cancers, except for classic Hodgkin lymphoma.
  • Pediatric hypermutated and SMARCB1-deficient cancers exhibit promising responses to ICIs.
  • Enhanced neoantigen expression and tumoral inflammation are likely drivers of response in these subsets.

Conclusions:

  • ICIs have a limited but evolving role in pediatric oncology.
  • Specific molecular subtypes of pediatric cancer, such as hypermutated and SMARCB1-deficient types, represent promising candidates for ICI therapy.
  • Further dedicated clinical trials are necessary to confirm the efficacy of ICIs in these selected pediatric cancer populations.